Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate

T.T. Tan¹, A.A. Alzaid¹, N. Sutcliffe¹, M.D. Gardner,² J.A. Thomson¹ and I.T. Boyle¹

University Departments of ¹Medicine and ²Biochemistry, Royal Infirmary, Glasgow G31 2ER, UK.

Summary: Two patients had symptomatic hypercalcaemia accompanying thyrotoxicosis, despite initial treatment with volume repletion, beta blockade and antithyroid drugs. They were further managed with intravenous infusions of aminohydroxypropylidene diphosphonate resulting in rapid normalization of the serum calcium, with relief of symptoms. Aminohydroxypropylidene diphosphonate effectively suppressed the increased bone resorption of thyrotoxicosis without any undesirable adverse effects.

Introduction

The tendency towards hypercalcaemia in thyrotoxicosis has been documented.¹ Reported incidence of hypercalcaemia in thyrotoxicosis is between 8–22%.²⁻³ Usually the hypercalcaemia is mild but occasionally it is severe enough to be symptomatic or even life-threatening, and urgent treatment specifically directed to the hypercalcaemia is therefore occasionally desirable.

Previous studies¹⁻⁴⁻⁶ have shown the hypercalcaemia of thyrotoxicosis to be due primarily to increased bone resorption, although relative immobilization during hospitalization may sometimes play a contributory role.³ Intravenous infusion of aminohydroxypropylidene diphosphonate (APD) has been shown by ourselves and others⁷⁻¹⁰ to be effective and safe in treating malignancy-induced hypercalcaemia by inhibiting bone resorption. The efficacy of intravenous infusion of APD in the treatment of hypercalcaemia of thyrotoxicosis was evaluated in the following two patients.

Case reports

Case 1

A 28 year old woman with mild chronic renal failure resulting from a neurogenic bladder due to spinal bifida and recurrent urinary tract infection was admitted with a 3 month history of progressive weight loss, anorexia, intractable vomiting, dehydration, wasting, sinus tachycardia and a small goitre. Initial and subsequent biochemistry (Table I) confirmed the diagnosis of thyrotoxicosis complicated by hypercalcaemia. Thyroid hormones and thyroid stimulating hormone (TSH) were measured by radio-immunoassay. Plasma parathyroid hormone (PTH) was measured using a double-antibody (Wellcome AS 211/23) radio-immunoassay which recognizes both N and C terminal ends of the hormone molecule, whilst the other biochemical values in Table I were measured as previously described,⁸⁻¹¹ with serum calcium levels being corrected to a serum albumin of 47 g/l.

Despite one week of treatment with intravenous saline rehydration and oral carbimazole 45 mg/day, she remained symptomatic and hypercalcaemic at 3.35 mmol/l. Two infusions of APD 5mg each in 250ml normal saline over 4 hours were then given at 4 day intervals, with restoration of serum calcium and true fasting urinary calcium:creatinine to normal 5 days after the first infusion (Figure 1), in addition to symptomatic improvement. There were no untoward side effects and she has remained normocalcaemic since.

Case 2

A 43 year old man presented with typical symptoms and signs of thyrotoxicosis. In addition, he had prominent complaints of polyuria, polydipsia, nausea and vomiting of one month's duration. The clinical diagnosis of thyrotoxicosis-induced hyper-
Table 1  Biochemical findings in the two patients with thyrotoxic hypercalcaemia at diagnosis

<table>
<thead>
<tr>
<th></th>
<th>Case 1</th>
<th>Case 2</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted calcium (mmol/l)</td>
<td>3.20</td>
<td>3.20</td>
<td>2.2–2.6</td>
</tr>
<tr>
<td>Phosphate (mmol/l)</td>
<td>1.90</td>
<td>1.70</td>
<td>0.7–1.4</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>455*</td>
<td>230</td>
<td>80–280</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>29</td>
<td>37</td>
<td>35–55</td>
</tr>
<tr>
<td>Urea (mmol/l)</td>
<td>28.1</td>
<td>8.5</td>
<td>2.5–8.0</td>
</tr>
<tr>
<td>Creatinine (µmol/l)</td>
<td>250</td>
<td>80</td>
<td>40–130</td>
</tr>
<tr>
<td>Ca:Cr† (mmol:mmol)</td>
<td>1.79</td>
<td>2.42</td>
<td>0.03–0.70</td>
</tr>
<tr>
<td>OHP:Cr‡ (mmol:mmol)</td>
<td>—</td>
<td>0.200</td>
<td>undetectable–0.030</td>
</tr>
<tr>
<td>PTH (ng/l)</td>
<td>250</td>
<td>&lt;200</td>
<td>undetectable–600</td>
</tr>
<tr>
<td>Thyroxine (nmol/l)</td>
<td>249</td>
<td>326</td>
<td>55–144</td>
</tr>
<tr>
<td>Triiodothyronine (nmol/l)</td>
<td>6.7</td>
<td>14.6</td>
<td>0.9–2.8</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>&lt;0.8</td>
<td>&lt;0.8</td>
<td>undetectable–5.0</td>
</tr>
</tbody>
</table>

*Isoenzymes indicate hepatic origin; †Ca:Cr = urinary calcium:creatinine ratio; ‡OHP:Cr = urinary hydroxyproline: creatinine ratio

---

Figure 1  Case 1 – effect of APD on adjusted serum calcium and indices of bone resorption. N.R.-normal range.

---

calcaemia was made and substantiated biochemically (Table I). Propylthiouracil 400mg/day, propranolol 120mg/day and volume repletion with intravenous saline were started. At day 19 of treatment he was still hypercalcaemic with persistence of nausea and polyuria. At this stage a single infusion of 15mg APD in 500ml normal saline over 4 hours was administered with rapid fall of serum calcium (Figure 1) and urinary excretion of calcium and hydroxyproline to normal (Figure 2). Transient pyrexia was the only observed side effect, and has been noted previously by ourselves8 and others (O.L.M. Bijvoet, 1978, personal communication). The pyrexia lasts only an hour or two and appears to accompany the initial rapid change in bone resorption although the mechanism is uncertain. Transient pyrexia may also accompany the use of APD in the management of Paget’s disease. The normalization of his serum calcium was sustained.

Discussion

The marked increase in true fasting urinary excretion of calcium and hydroxyproline in both cases (Figures 1 and 2) are consistent with increased bone resorption as reported by earlier studies.1–6 In both patients PTH was appropriately suppressed.

Oral propranolol in conventional dosage as used in the second case for control of thyrotoxic symptoms is ineffective by itself in lowering serum calcium.13–14 The calcium lowering effect of antithyroid drugs in both cases was slow but sustained. The first and second cases were still hypercalcaemic after 10 and 19 days of treatment respectively (Figures 1 and 2) in accord with a previous report15 that normalization of serum calcium concentration might take 2 to 8 weeks of antithyroid therapy. In contrast, infusions of APD rapidly normalized the serum calcium concentration in 1 and 5 days (Figures 2 and 1) in cases 2 and 1.
respectively by inhibition of bone resorption as indicated by the rapid fall of urinary calcium and hydroxyproline to normal (Figures 1 and 2) with transient pyrexia in case 2 as the only side effect. Relief of symptoms paralleled the falls in serum calcium.

In contrast to intravenous calcitonin and propranolol, the normalized serum calcium concentration was sustained without further infusion of APD. This could be due both to the more prolonged calcium lowering action of APD, as described up to 8 days in a study on hypercalcaemia of malignancy, and to the continued use of antithyroid drugs which has a slower but sustained effect.

In both cases vomiting was a prominent feature of the hypercalcaemia and delayed the diagnosis in the first case.

The hypoalbuminaemia and hyperphosphataemia noted in both cases (Table I) are recognized features of thyrotoxicosis. The alkaline phosphatase seen in case 1 was inappropriately high to be derived from bone and a hepatic origin, as suggested by concomitant elevation of other liver enzymes, was subsequently confirmed by an alkaline phosphatase isoenzyme study. A normocalcaemic relapse 3 months later with similar elevation of liver enzymes suggests association of the two conditions. A causal relationship between jaundice and thyrotoxicosis has previously been reported.

In conclusion, one or two infusions of APD used concomitantly with volume repletion and antithyroid drugs is an effective and safe method of controlling significant and symptomatic hypercalcaemia in thyrotoxicosis.

Acknowledgements

Aminohydroxypropylidene diphosphonate for intravenous use was supplied by Ciba-Geigy Pharmaceuticals.

We would like to thank Mrs Legrix for secretarial assistance.

References

Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.

T. T. Tan, A. A. Alzaid, N. Sutcliffe, M. D. Gardner, J. A. Thomson and I. T. Boyle

Postgrad Med J 1988 64: 224-227
doi: 10.1136/pgmj.64.749.224

Updated information and services can be found at:
http://pmj.bmj.com/content/64/749/224

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/